IVDR Era: what changes for manufacturers (and why it’s an opportunity)

IVDR Era: what changes for manufacturers (and why it’s an opportunity)

The transition from the old In Vitro Diagnostic Directive (IVDD) to the In Vitro Diagnostic Regulation (IVDR 2017/746) is arguably the most profound regulatory shift the European diagnostics industry has ever seen.

For years, the vast majority of IVD medical devices could be self-certified by manufacturers. Under the IVDR, that reality has been completely upended. It is no longer just a hurdle for regulatory affairs departments; it is a core business challenge that reshapes how diagnostic products are designed, manufactured, and maintained on the market.

Here is a look at what has truly changed for manufacturers, and why navigating this new era requires a shift from “compliance checking” to strategic partnership.

The great reclassification: no more easy self-certification

Under the old directive, roughly 80% of all IVDs on the market could be self-certified. Under IVDR’s new risk-based classification system (Classes A to D), that statistic has flipped. Now, an estimated 80% or more of all IVDs require the oversight of a Notified Body (NB) to achieve or maintain market access.

Scientific validity and clinical evidence: higher stakes

The IVDR demands an unprecedented level of data robustness. Manufacturers must continuously prove three pillars of evidence:

• Scientific Validity: The association of the analyte with the clinical condition.
• Analytical Performance: The ability of the device to correctly detect or measure a specific analyte (sensitivity, specificity, accuracy).
• Clinical Performance: The ability of the device to yield results that are correlated with a particular clinical condition or a physiological/pathological state.

Moreover, this is not a ‘one-and-done’ exercise. Performance evaluation is a continuous lifecycle process; through mandatory Post-Market Performance Follow-up (PMPF), manufacturers must actively and continuously collect real-world data to update and confirm these three pillars as long as the device is on the market.

Quality and supply chain control

To achieve this level of clinical and analytical robustness, a diagnostic kit is only as strong as its weakest component. The IVDR places heavy emphasis on the control of the supply chain. Manufacturers must guarantee full lot-to-lot reproducibility from raw material vendors (like antigens and antibodies) to ensure process stability. Concurrently, true regulatory traceability is enforced through the Unique Device Identification (UDI) system, guaranteeing transparency, post-market safety tracking, and efficient vigilance throughout the entire lifecycle of the finished kit on the laboratory shelf.

From regulatory hurdle to competitive advantage

While the road to IVDR compliance is resource-intensive, it also acts as a natural market filter. Companies that adapt quickly are gaining a significant competitive edge.

However, many diagnostic developers may face significant challenges in absorbing the substantial operational costs, specialized QA/RA workload, and manufacturing infrastructure required to achieve and maintain compliance.

The power of specialized partnership

This is exactly where the concept of a smart ecosystem comes into play. Partnering with an organization that possesses a dual soul – deep scientific expertise in diagnostics development coupled with robust, certified CDMO manufacturing capabilities – changes the game.

• De-risk the Technical Documentation: Leverage a partner with already validated manufacturing processes, qualified equipment, and robust environmental controls, simplifying the data package

The IVDR era doesn’t have to mean the end of agility in diagnostic innovation. By choosing the right industrial and regulatory allies, manufacturers can transform a complex compliance mandate into a launchpad for superior, globally trusted diagnostic products.